56046-25-4

Basic information

• Product Name: 9-BENZYL-2-CHLORO-9H-PURIN-6-YLAMINE
• Synonyms: 9-BENZYL-2-CHLORO-9H-PURIN-6-YLAMINE;9-benzyl-2-chloro-9H-purin-6-aMine;2-Chloro-9-(phenylmethyl)-9H-purin-6-amine;2-Chloro-9-benzyladenine;9-Benzyl-2-chloro-9H-adenine;9-Benzyl-2-chloroadenine
• CAS NO: 56046-25-4
• Molecular Formula: C₁₂H₁₀ClN₅
• Molecular Weight: 259.6943
• Mol File: 56046-25-4.mol

Chemical Properties

• Melting Point: 228-229℃
• Boiling Point: 430.8°Cat760mmHg
• Flash Point: 214.4°C
• Appearance: /
• Density: 1.51
• Vapor Pressure: 1.26E-07mmHg at 25°C
• Refractive Index: 1.75
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 9-BENZYL-2-CHLORO-9H-PURIN-6-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 9-BENZYL-2-CHLORO-9H-PURIN-6-YLAMINE(56046-25-4)
• EPA Substance Registry System: 9-BENZYL-2-CHLORO-9H-PURIN-6-YLAMINE(56046-25-4)

Safety Data

• Hazardous Substances Data: 56046-25-4(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry and Drug Development:
9-Benzyl-2-chloro-9H-purin-6-ylamine is used as a chemical compound in medicinal chemistry and drug development for its purine-based structure, which is found in many biologically active compounds. Its unique chemical properties and potential interactions with biological systems make it a promising candidate for the development of new therapeutic agents.
Used as a Research Tool in Biochemistry and Pharmacology:
9-Benzyl-2-chloro-9H-purin-6-ylamine is used as a research tool in biochemistry and pharmacology to study the effects of purine modifications on biological systems. Its unique structure allows researchers to investigate the role of purines in various biological processes and their potential as therapeutic targets.
Used in the Treatment of Certain Diseases or Conditions:
Although further research is needed to determine its specific pharmacological properties and potential medical applications, 9-benzyl-2-chloro-9H-purin-6-ylamine may have potential therapeutic uses in the treatment of certain diseases or conditions. Its purine-based structure and unique chemical properties could offer new avenues for the development of targeted therapies and treatments.

InChI:InChI=1/C12H10ClN5/c13-12-16-10(14)9-11(17-12)18(7-15-9)6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H2,14,16,17)

Upstream product

• 100-44-7 benzyl chloride 
• 1839-18-5 2-chloroadenine 
• 203436-18-4 9-benzyl-2-chloro-N-(4-methoxybenzyl)-9H-purin-6-amine 
• 100-39-0 benzyl bromide 
• 5451-40-1 2,6 dichloropurine 
• 83545-29-3 9-benzyl-6-benzyloxy-9H-purine 
• 79064-26-9 9-benzyl-2,6-dichloro-9H-purine 

Downstream Products

• 83492-17-5 9-benzyl-2-n-propylthio-9H-adenine 
• 226907-97-7 6-Amino-9-benzyl-2-(sec-butylamino)purine 
• 7674-36-4 9-Benzylpurine-2,6-diamine 
• 229025-10-9 9-benzyl-8-bromo-2-chloroadenine 
• 226908-00-5 6-Amino-9-benzyl-2-cyclohexylaminopurine 
• 226908-01-6 6-Amino-2-anilino-9-benzylpurine 
• 226908-03-8 9,N²-dibenzyl-N²-methyl-9H-purine-2,6-diamine 
• 226907-99-9 6-Amino-9-benzyl-2-benzylaminopurine 
• 226908-63-0 6-Amino-9-benzyl-2-(2-hydroxyethoxy)-9H-purin-6-amine 
• 226907-61-5 6-Amino-9-benzyl-2-pentylthiopurine 
• 226908-27-6 6-Amino-9-benzyl-2-(2-ethoxyethoxy)purine 
• 226907-60-4 6-Amino-9-benzyl-2-(sec-butylthio)purine 
• 226907-59-1 6-Amino-9-benzyl-2-(isobutylthio)purine 
• 226907-84-2 6-Amino-9-benzyl-2-pentoxypurine 

Relevant articles and documents

Ferrocene-Modified Purines as Potential Electrochemical Markers: Synthesis, Crystal Structures, Electrochemistry and Cytostatic Activity of (Ferrocenylethynyl)- and (Ferrocenylethyl)purines

Palladium-catalyzed Sonogashira cross-coupling reactions of halo-purines 9-benzyl-6-chloropurine (2a), 9-benzyl-8-bromoadenine (2b), and 9-benzyl-2-chloroadenine (2c) with ethynylferrocene (1) gave the corresponding (ferrocenylethynyl)purines 3a-c in moderate to good yields. Catalytic hydrogenation of these alkynes over Pd/C afforded the respective saturated [2-(ferrocenyl)ethyl]purines 4a-c. The crystal structures 3a, 3b, 4a and 4b as determined by X-ray diffraction show interesting solid-state interactions, markedly different for purines 3a and 4a on one hand and adenines 3b and 4b that possess a free amino group on the other. Electrochemistry of electrochemically labelled purines 3 and 4 has been studied by voltammetry and cyclic voltammetry on platinum disc electrode and the experimental oxidation potentials were confirmed and explained by ionization potentials from theoretical DFT calculations. Several compounds of this series exhibited a considerable cytostatic effect.

COMPOUNDS AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR

The present invention provides compounds of Formula (I) shown above and their pharmaceutically acceptable salt, solvates, isomers, or prodrugs, as well as pharmaceutical compositions containing these compounds. Also provided by the invention is a method for treating a disorder mediated by macrophage migration inhibitory factor in a subject, comprising administering to the subject in need thereof a compound or a pharmaceutical composition of this invention.

COMPOUNDS FOR TREATING CYSTIC FIBROSIS

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) for the treatment of cystic fibrosis. The invention also relates to a process for manufacturing compounds of Formula (I).

Facile syntheses of functionalized toll-like receptor 7 agonists

Protein conjugates of toll-like receptor 7 agonists have been shown to elicit powerful immune responses. In order to facilitate our studies in this area our group has developed efficient syntheses for a number of functionalized derivatives that retain imm

NOVEL BICYCLIC BROMODOMAIN INHIBITORS

The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.

SPRAY DRIED FORMULATION

Pharmaceutical compositions comprising a poorly water soluble ionizable drug, a cationic species and a dispersion polymer are disclosed, together with a process for forming the compositions. The neutral form of the drug has (i) a solubility of less than 1 mg/mL in aqueous solution at a pH between 6 and 7, (ii) a solubility of less than 20 mg/mL in a volatile organic solvent, and (iii) an acidic pKa value of greater than 5. At least 90 wt% of the drug in the solid dispersion being in a non-crystalline form. The drug, the cationic species, and the dispersion polymer constitute at least 80 wt% of the solid dispersion.

Synthesis of 2-alkoxy-8-hydroxyadenylpeptides: Towards synthetic epitope-based vaccines

The preparation of three different 2-alkoxy-8-hydroxyadenylpeptide conjugates has been accomplished by solid-phase synthesis combined with 'on-resin' Cu(I) catalyzed Huisgen cycloaddition. The immunogenicity of the compounds has been evaluated in IL-12 production and antigen presentation assays.

2-AMIDO-6-AMINO-8-OXOPURINE DERIVATIVES AS TOLL-LIKE RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS, SUCH AS HEPATITIS C

This invention relates to purine derivatives, to processes for their preparation, to compositions containing them and to their use. The present invention provides compounds of formula (I) wherein R1, R2, R3, R9, R9a and Y are defined in the description. More particularly, the present invention relates to the use of purine derivatives in the treatment of a variety of viral infections and immune or inflammatory disorders, including those in which the modulation, in particular agonism, of Toll-Like Receptors (TLRs) is implicated. Accordingly, the compounds of the invention are useful in the treatment of infectious disease such as Hepatitis (e.g. HCV, HBV), genetically related viral infections, inflammatory diseases such as asthma and arthritis, and cancer.

Synthesis and structure-activity relationships of 2-amino-8- hydroxyadenines as orally active interferon inducing agents

Recently, we have reported the 8-hydroxyadenine derivatives (2-4) as a novel class of interferon (IFN) inducing agents. In the present study, a series of 8-hydroxyadenines, which possess various amino moieties at the adenine C(2)-position, were synthesized and evaluated for their ability to induce endogenous IFN in comparison to the known active agent, Imiquimod. Among the compounds prepared, compound 9o possessing a 2-methoxyethylamino group at C(2)-position of adenine was found to exhibit potent IFN inducing activity in vivo. Compound 9o induced IFN from the dosage of 0.1 mg/kg, which was 30-fold potent than that of Imiquimod, and showed a good oral bioavailability (F=81%).

Heterocyclic compounds

The present invention relates to a heterocyclic compound of the following general formula (I): wherein X is sulfur atom, oxygen atom or —NR3— (R3may form a heterocyclic ring or a substituted heterocyclic ring with R1via the nitrogen atom), R1is alkyl group, substituted alkyl group, aryl group, substituted aryl group, heterocyclic group or substituted heterocyclic group, and R2is hydrogen atom, halogen atom etc.; or its pharmaceutically acceptable salt and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases comprising the compound (I) or its pharmaceutically acceptable salt as active ingredients.